Systemic anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) Ab was the first licensed ICI against advanced metastatic melanoma [100], and was then quickly followed by anti-programmed cell death ligand and protein 1 (PD-L1/PD-1) Abs. This evidence concerns the gene CTLA4 and metastatic melanoma.